Get started
Author

Giada Rizzi

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
2014 · M. Aapro, H. Rugo, et al. · Annals of Oncology · 250
PDF
Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
2014 · P.J. Hesketh, G. Rossi, et al. · Annals of Oncology · 228
PDF
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
2014 · R.J. Gralla, S.M. Bosnjak, et al. · Annals of Oncology · 189
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
2016 · Matti Aapro, Meinolf Karthaus, et al. · Supportive Care in Cancer · 47
PDF
Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy
2018 · L. Schwartzberg, E. Roeland, et al. · Annals of Oncology · 40
Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
2019 · Lee Schwartzberg, Rudolph Navari, et al. · The Oncologist · 33
PDF
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens
2016 · Karin Jordan, Richard Gralla, et al. · Supportive Care in Cancer · 25
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC)
2015 · Meinolf Karthaus, Csőszi Tibor, et al. · Supportive Care in Cancer · 19
PDF
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program
2016 · Matti Aapro, Paul J. Hesketh, et al. · The Oncologist · 17
Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
2019 · Lee Schwartzberg, Meinolf Karthaus, et al. · Cancer Medicine · 16
PDF
Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials
2017 · Hope S. Rugo, Giorgia Rossi, et al. · The Breast · 13
Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.
2014 · Matti S. Aapro, Meinolf Karthaus, et al. · Journal of Clinical Oncology · 12
Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients
2016 · Matti Aapro, Karin Jordan, et al. · Journal of Geriatric Oncology · 8
No Evidence Of Increased Cyclophosphamide Toxicity Associated With The Antiemetic Agent NEPA, a Fixed-Dose Combination Of Netupitant and Palonosetron
2013 · Lee Schwartzberg, Cristina Oprean, et al. · Blood · 8
Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy
2018 · SneZana M. Bosnjak, Ljiljana Stamatovic, et al. · International Journal of Gynecological Cancer · 6
Evaluation of nausea control with NEPA, a novel oral combination antiemetic.
2014 · Snezana Bosnjak, Lee Steven Schwartzberg, et al. · Journal of Clinical Oncology · 6
Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
2019 · Galina Kurteva, Nataliya Chilingirova, et al. · European Journal of Pharmaceutical Sciences · 5
Should all antiemetic guidelines recommend adding a NK1 receptor antagonist (NK1RA) in patients (pts) receiving carboplatin (carbo)? Efficacy evaluation of NEPA, a fixed combination of the NK1RA, netupitant, and palonosetron.
2015 · Karin Jordan, Richard J. Gralla, et al. · Journal of Clinical Oncology · 5
75 Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)
2014 · P. Jahn, K. Jordan, et al. · European Journal of Oncology Nursing · 5
Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
2013 · Matti S. Aapro, Giorgia Rossi, et al. · Journal of Clinical Oncology · 5
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
2013 · Matti S. Aapro, Giorgia Rossi, et al. · Journal of Clinical Oncology · 5
Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
2013 · Paul Joseph Hesketh, Giorgia Rossi, et al. · Journal of Clinical Oncology · 5
Phase III study of palonosetron (PALO) given as 30-min IV infusion (IV inf) versus 30-sec IV bolus (IV bol) for prevention of chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy (HEC).
2017 · Meinolf Karthaus, Péter Szabò, et al. · Journal of Clinical Oncology · 4
Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron
2017 · L. Schwartzberg, Z. Andric, et al. · Annals of Oncology · 4
PDF
Cardiac Safety of NEPA, a Fixed-Dose Antiemetic Combination, Administered Prior to Anthracycline-Based Chemotherapy
2014 · Meinolf Karthaus, Matti Aapro, et al. · Blood · 4
Works count: 40
Citation count: 986
H-index: 12
I10-index: 12
Year
Topic
Type